Preparation method and application of liver-soothing and qi-guiding preparation
The effective ingredients in Shugan Shunqi Pills were extracted through distillation extraction and water decoction, and a variety of dosage forms were prepared in combination with the inclusion agent technology, which solved the problem of single dosage form of Shugan Shunqi Pills and low transfer rate of active ingredients, and improved the biological Utilization and medication compliance are suitable for long-term use in patients with diabetes.
Patent Information
- Application Number
- CN202411032670.1
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2044-07-30
AI Technical Summary
The existing Shugan Shunqi Pills have a single dosage form, low transfer rate of active ingredient, unsatisfactory bioavailability, limited population, poor compliance with medication, especially for diabetic patients.
Use distillation extraction and water decoction to extract the active ingredients in the medicinal materials, and combine the inclusion agent technology to prepare a variety of dosage forms, such as tablets, capsules and oral liquids, to improve the bioavailability of the drug and the compliance of the medication, and to reduce honey ingredients to suit Diabetic patients.
It improves the bioavailability of drugs and the compliance of medication, expands the safety of medication for applicable populations, especially those with diabetes, enhances the efficacy of medication, and reduces the waste of medicinal materials resources.
Smart Images

Figure SMS_1 
Figure SMS_2 
Figure SMS_3
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of traditional Chinese medicine preparations, and in particular to a preparation method and application of a liver-soothing and qi-regulating preparation. Background Art
[0002] Shugan Shunqi Pills are a pure Chinese medicine preparation made by adding and subtracting the optimized version of Chaihu Shugan Powder in Jingyue Complete Works. It is composed of 13 Chinese medicines, including Bupleurum, Cyperus (vinegar-processed), White Peony Root, Curcuma, Fructus Aurantii Immaturus (fried), Magnolia Officinalis, Aucklandia Rhizoma, Citrus Palmatum, Corydalis (vinegar-fried), Ligusticum chuanxiong, Amaranthus, Tangerine Peel, and Licorice. Shugan Shunqi Pills (National Medicine Standard Z20026802, Standard Number: WS-11169 (ZD-1169)-2002-2011Z) are large black honey pills, each weighing about 9g. Its functions and indications are: soothing the liver, regulating qi, and relieving pain. It is used for the symptoms of liver depression and qi stagnation, with symptoms of: fullness in the flanks, stabbing pain in the stomach, vomiting and nausea, belching and acid reflux. Experimental studies have shown that Shugan Shunqi Pills can effectively improve the symptoms of functional dyspepsia model and gastrointestinal motility disorder model, inhibit gastric acid secretion, promote gastrointestinal motility, improve serum gastrointestinal hormone levels, increase pepsin activity, and also have obvious pharmacological effects of increasing intestinal absorption and analgesia.
[0003] In the prior art, Shugan Shunqi Pills are made by grinding raw medicinal materials into powder, sterilizing, and making pills with a large amount of honey (for the preparation process, see Shugan Shunqi Pills Standard WS-11169 (ZD-1169)-2002-2011Z). The bioavailability of the active ingredients in the pills prepared by grinding raw medicinal materials into powder is not ideal. After the patient takes the medicine, the raw medicinal materials in the pills need to be processed by the human digestive tract before some of the active ingredients can be dissolved and have the opportunity to be absorbed by the digestive tract and then play a role. Due to the limited temperature and gastric juice volume of the intestine, the utilization rate of the active ingredients of this type of product using raw medicinal materials as medicine is very low, and the utilization rate is very slow, resulting in no obvious drug effect. In addition, Shugan Shunqi Pills contain a large amount of honey and are of large specifications, resulting in poor compliance of patients taking the medicine, and diabetics cannot take it for a long time. Therefore, it is urgent to improve the dosage form of Shugan Shunqi Pills to improve the bioavailability of the drug, expand the population applicable to the drug, improve the compliance of patients taking the medicine and improve the efficacy. Summary of the invention
[0004] The present invention aims to provide a liver-soothing and qi-soothing preparation to solve the technical problems of the prior art of single dosage form of the liver-soothing and qi-soothing pills, low transfer rate of effective ingredients, unsatisfactory bioavailability of the drug, limited applicable population and poor compliance of drug administration.
[0005] In order to achieve the above object, the present invention adopts the following technical scheme:
[0006] A method for preparing a liver-soothing and qi-regulating preparation comprises the following steps performed in sequence:
[0007] S1: extracting the medicinal material by distillation to obtain a distilled water phase, a distilled oil phase and medicinal residues; extracting the medicinal residues by decocting in water to obtain a decoction, and combining the decoction and the distilled water phase to obtain an extract;
[0008] S2: using an inclusion agent to carry out inclusion treatment on the distilled oil phase to obtain an inclusion compound solution or inclusion compound powder;
[0009] After the extract is concentrated, it is prepared into an oral preparation together with an inclusion compound solution or inclusion compound powder and auxiliary materials.
[0010] Further, in S1, the medicinal raw materials include, by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis and 55-65 parts of Amaranthus;
[0011] Preferably, the medicinal raw materials include: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma Radix, 31.4 parts of Citrus Hand, 31.4 parts of Aucklandia Root, 31.4 parts of Tangerine Peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus orchioides.
[0012] Further, in S1, the distillation extraction adopts an intermittent distillation extraction method, and the intermittent distillation extraction is performed alternately by fierce fire distillation and slight boiling distillation;
[0013] Preferably, the intermittent distillation extraction uses water or an alcohol solution as the extraction solvent;
[0014] Preferably, the total extraction time is 1-8 hours;
[0015] Preferably, the intermittent distillation extraction process is carried out in a cycle of first 10-20 minutes of high-fire distillation extraction and then 10-20 minutes of micro-boiling distillation extraction.
[0016] The technical solution adopts a distillation extraction method of alternating low heat and high heat to extract volatile oil from medicinal materials, thereby improving the yield of volatile oil.
[0017] Further, in step S1, the method for extracting the medicinal residue by decoction in water is specifically as follows: adding water 6-8 times the mass of the medicinal raw material for a first decoction extraction for 2-3 hours; adding water 6-8 times the mass of the medicinal raw material and adjusting the pH value to 7.0-7.5, performing a second decoction extraction for 2-3 hours, and mixing the extracts obtained by the first decoction extraction and the second decoction extraction to obtain a decoction.
[0018] During the extract preparation stage, the pH value of the extraction system for the second decoction extraction needs to be adjusted to ensure the extraction rate of the active ingredients.
[0019] Further, in S2, the oral preparation is a liver-soothing and gas-soothing composition tablet, which is prepared by the following steps:
[0020] S2-1-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution or concentrate and dry the inclusion compound solution to obtain an inclusion compound powder;
[0021] The extract is concentrated and then dried to obtain a dry paste, and the dry paste is crushed and sieved to obtain ointment powder;
[0022] S2-1-2: taking the inclusion compound solution or inclusion compound powder, the ointment powder and the granulation excipients and mixing them evenly, and then granulating them to obtain drug granules;
[0023] Preferably, the granulation excipients include cross-linked polyvinylpyrrolidone and microcrystalline cellulose;
[0024] S2-1-3: mixing the drug particles and tableting excipients at 15-20 rpm for 10-20 minutes to obtain a total mixture;
[0025] Preferably, the tableting auxiliary material is magnesium stearate;
[0026] S2-1-4: The total mixture is subjected to tableting and coating treatment to obtain liver-soothing and qi-regulating composition tablets.
[0027] Further, in S2, the oral preparation is a capsule of the soothing liver and shunning qi composition, which is prepared by the following steps:
[0028] S2-2-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution or concentrate and dry the inclusion compound solution to obtain an inclusion compound powder;
[0029] The extract is concentrated and then dried to obtain a dry paste, and the dry paste is crushed and sieved to obtain ointment powder;
[0030] S2-2-2: taking the inclusion compound solution or inclusion compound powder, the ointment powder and the pregelatinized starch, mixing them evenly and granulating them to obtain drug granules;
[0031] S2-2-3: mixing the drug particles and the micro-powdered silica gel to obtain a total mixture;
[0032] S2-2-4: Fill the total mixture into empty capsules to obtain liver-soothing and qi-regulating composition capsules.
[0033] Further, in S2, the oral preparation is a soothing liver and shunning qi composition oral liquid, which is prepared by the following steps:
[0034] S2-3-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution or concentrate and dry the inclusion compound solution to obtain an inclusion compound powder;
[0035] Concentrating the extract into an extract or a fluid extract;
[0036] S2-3-2: Take the extract or fluid extract, inclusion compound solution or inclusion compound powder, sweetener, and preservative, mix them, and adjust the pH value to 4-5. After fixing the volume, filter and sterilize to obtain the oral liquid of soothing liver and relieving qi composition.
[0037] Further, in S2, the liver-soothing and qi-soothing composition granules are prepared by the following steps:
[0038] S2-4-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution, and then concentrate and dry the inclusion compound solution to obtain an inclusion compound powder;
[0039] The extract is concentrated and dried to obtain a dry paste, and the dry paste is crushed and sieved to obtain ointment powder;
[0040] S2-4-2: taking the sweetener, flavor, filler, inclusion compound powder and ointment powder, and wet granulating and drying them to obtain mixed granules; preferably, the filler is any one of dextrin or soluble starch;
[0041] S2-4-3: Mix the mixed granules and the inclusion compound powder to obtain a total mixture, and prepare the liver-soothing and qi-regulating composition granules.
[0042] The technical solution also provides a method for preparing a soothing liver and shunning qi preparation and a soothing liver and shunning qi preparation prepared by the method.
[0043] The technical scheme also provides a method for preparing a medicine for treating functional dyspepsia, or for treating flank distension, epigastric pain, vomiting, noisy stomach, belching and acid reflux caused by liver depression and qi stagnation.
[0044] The principle and beneficial effects of this technical solution are:
[0045] This technical solution improves the extraction method of the active ingredients in the raw materials of the Shugan Shunqi preparation, and provides a preparation method for a variety of dosage forms, which can effectively improve the patient's compliance with medication. Specifically, the traditional preparation method of the Shugan Shunqi pill is usually to directly grind the medicinal materials into powder for use as medicine. The utilization rate of its active ingredients by the human body is very low, and the utilization rate is very slow, resulting in poor efficacy and a certain degree of waste of medicinal resources. Although there are attempts to extract some medicinal materials in the prior art, such as patent CN101461925B, the scheme of grinding part of the ethanol extract of the Shugan Shunqi composition medicinal materials and part of the raw medicinal materials into powder for use as medicine, and then mixing the extract with the powder to prepare a finished drug. However, these operation methods do not make full use of the distilled oil phase components in the medicinal materials. This technical solution extracts the distilled oil phase components in the medicinal materials for the first time (especially Cyperus rotundus, Curcuma aromatica, Citrus aurantium, Magnolia officinalis, Aucklandia lappa, Citronella bergamot, Chuanxiong, Tangerine peel and Amaranthus chinensis, which are rich in distilled oil phase components). These distilled oil phase components have a good effect of soothing the liver and regulating qi, and the effective ingredients are fully utilized, so that the improved Shugan Shunqi preparation has further improved efficacy. In addition, the use of intermittent fierce fire and slow fire in the distillation and extraction process can improve the yield of the distilled oil phase. After the intermittent distillation and extraction, the pH value is appropriately adjusted during the decoction and extraction of the drug residue to increase the amount of the characteristic components obtained. At the same time, this technical solution changes the dosage form of the traditional Shugan Shunqi Pills into tablets, capsules, oral liquids and granules, enriching the drug form of the liver Shunqi composition, which helps to improve the patient's compliance with medication. At the same time, the product of this technical solution does not contain ingredients such as honey and is suitable for diabetic patients. While ensuring that the daily dose of crude drugs remains unchanged, the daily dose is reduced, and the drug is applicable to a wider range of people. In addition, in the process of preparing various dosage forms, the use of appropriate inclusion agents, fillers and disintegrants can further improve the quality of the finished product. DETAILED DESCRIPTION
[0046] The specific embodiments listed in the present invention are only examples of the present invention, and the present invention is not limited to the specific embodiments described below. For those skilled in the art, any equivalent modifications and substitutions made to the embodiments described below are also within the scope of the present invention. Therefore, the equalization and modification made without departing from the spirit and scope of the present invention should be included in the scope of the present invention.
[0047] In the examples, if the specific conditions are not specified, the conditions are carried out according to normal conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified for all reagents or instruments, they are all conventional products that can be purchased commercially. In order to better illustrate the present invention, numerous specific details are provided in the specific embodiments below. It should be understood by those skilled in the art that the present invention can be implemented equally without certain specific details. In other embodiments, methods, means, equipment and steps well known to those skilled in the art are not described in detail to highlight the gist of the present invention.
[0048] Unless otherwise defined, all technical and scientific terms used herein have the same meanings as those commonly understood by those skilled in the art. Unless otherwise specified, the units used in this specification are all international standard units, and the numerical values and numerical ranges appearing in the present invention should be understood to include the inevitable systematic errors in industrial production.
[0049] Example 1
[0050] The formula of the Shugan Shunqi preparation is shown in Table 1.
[0051] Table 1: Recipe composition
[0052]
[0053] This technical solution mainly improves the preparation process and dosage form, and does not adjust the formula composition. In order to facilitate experimental research, the subsequent experimental content uniformly adopts the following formula: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus (made with vinegar), 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium (fried), 31.4 parts of Curcuma Radix, 31.4 parts of Citrus Hand, 31.4 parts of Aucklandia Root, 31.4 parts of Tangerine Peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo (made with vinegar), and 58.85 parts of Amaranthus orientalis.
[0054] The extracts were prepared using the above raw materials, and the specific process was as follows:
[0055] Take 13 kinds of medicinal materials, including Magnolia officinalis, Chuanxiong, Cyperus rotundus (vinegar-processed), White Peony Root, Bupleurum Root, Fructus Aurantii Immaturus (fried), Curcuma Radix, Citrus Grandis, Aucklandia Root, Tangerine Peel, Licorice, Corydalis Root (vinegar-fried), and Amaranthus, add them into a volatile oil extractor, add 8-10 times of the weight of the medicinal materials in water (preferably 8 times of the amount of water, or an aqueous solution of alcohol can be used as the extraction solvent), and perform intermittent distillation extraction for 1-8 hours (preferably 3-6 hours, and more preferably 6 hours), and obtain three parts of distilled water phase, distilled oil phase, and medicinal residue after extraction, and then separate the distilled water phase, distilled oil phase, and medicinal residue, and sieve the distilled water phase through a 200-mesh sieve for standby use. The specific operation mode of intermittent distillation extraction is: distillation extraction with fierce fire for 10-20 minutes (preferably 10 minutes), adjusting the heat to control the distillation system to be in a slightly boiling state for 10-20 minutes (preferably 10 minutes), and circulate according to the above program until the extraction process is completed. That is, high-fire distillation and low-fire (slightly boiling heating) distillation are carried out intermittently. The prior art generally uses steam heating, and the heating power is controlled by controlling the steam pressure of the distillation equipment. High-fire means that the heating steam pressure is controlled within the range of 0.04-0.06MPa in actual operation, and low-boiling heating (low-fire heating) means that the steam pressure is controlled within the range of 0.01-0.02MPa.
[0056] After the intermittent distillation extraction is completed, the residue is decocted in water for two more times. The amount of water added for the first time is 6-8 times the weight of the medicinal material (preferably 7 times), and the decoction is performed for 2-3 hours (preferably 3 hours). The amount of water added for the second time is 6-8 times the weight of the medicinal material (preferably 7 times), and the pH value of the system consisting of the residue and water is adjusted to 7.0-7.5 (preferably 7.2) with sodium hydroxide during the second decoction. The decoction is performed for 2-3 hours (preferably 3 hours). Each time the decoction is performed, the medicinal liquid is passed through a 160-200 mesh sieve (preferably a 200 mesh sieve), and the distilled water phase and the two decoction liquids are combined for standby use (hereinafter referred to as the extract).
[0057] The extract and distilled oil phase are used to make various preparations. Among them, the distilled oil phase needs to be encapsulated with an inclusion agent; the extract needs to be concentrated and dried. The above are all common steps in the preparation process.
[0058] The method of using an inclusion agent to carry out inclusion treatment on the distilled oil phase is as follows: take 3-5 times the mass of volatile oil hydroxypropyl-β-cyclodextrin (inclusion agent), dissolve it in 3-5 times the mass of hydroxypropyl-β-cyclodextrin water; under stirring conditions of 40-60 rpm, add volatile oil (distilled oil phase) at a speed of 1-2 ml / min, stir for 1.5-2.5 hours after the addition is completed, and obtain inclusion compound solution; concentrate and dry to a moisture content of less than 5.0%, and then crush through an 80-100 mesh sieve to obtain inclusion compound powder. Preferably, the inclusion agent is hydroxypropyl-β-cyclodextrin.
[0059] The process of extract concentration and drying is as follows: the extract is concentrated into a clear paste with a relative density of 1.20-1.25, and then a dry paste is obtained by drying, and the dry paste rate is 24%-27%; the dry paste is crushed and passed through an 80-100 mesh sieve to obtain ointment powder.
[0060] Example 2
[0061] This embodiment provides a preparation method for a liver-soothing and gas-regulating composition tablet:
[0062] The distilled oil phase and the extract obtained in Example 1 (obtained using the optimal process parameters) were used to prepare liver-soothing and qi-regulating composition tablets.
[0063] The auxiliary materials and dosage ranges used in the preparation of tablets are: 4-8 parts of cross-linked polyvinylpyrrolidone (6 parts in the specific experiment), 10-20 parts of microcrystalline cellulose (15 parts in the specific experiment), and 0.75-1.5 parts of magnesium stearate (1.35 parts in the specific experiment). In addition, conventional gastric soluble coating powder is used to coat the prepared tablets, and its proportion of each tablet weight is controlled to be 2-3%. In the distilled oil phase inclusion step, auxiliary material hydroxypropyl-β-cyclodextrin is used, and its dosage is determined by the mass of the distilled oil phase. In the dry granulation step, pregelatinized starch is used, which is only used as a filling material.
[0064] The specific preparation method is:
[0065] (1) Preparation of distilled oil phase inclusion compound powder: Take 3-5 times (preferably 4 times) the mass of distilled oil phase hydroxypropyl-β-cyclodextrin, dissolve it in 3-5 times (preferably 4 times) the mass of hydroxypropyl-β-cyclodextrin water, add the distilled oil phase dropwise at a speed of 1-2 ml / min (control the speed at about 1 ml / min during the addition) under stirring conditions of 40-60 rpm (preferably 50 rpm), stir for 1.5-2.5 hours (preferably 2 hours) after the addition is completed, dry until the moisture content is less than 5.0%, and then pulverize through an 80-100 mesh sieve (preferably an 80 mesh sieve) to obtain an inclusion compound powder;
[0066] (2) The extract is subjected to conventional concentration and drying treatment, firstly the extract is concentrated to a relative density of 1.20-1.25 (30-70°C, measured by a Pomeranian specific gravity meter), and then the concentrated material is dried to obtain a dry paste, and the dry paste rate is controlled to be 24-27%. More specifically, the following method can be used:
[0067] Take the extract and start the single-effect concentrator, with the vacuum degree ≤-0.09Mpa, the temperature ≤75°C, and the steam pressure ≤0.30Mpa. Filter the extract through a bag filter with 250 mesh and transfer it into the single-effect concentrator, concentrate it to a relative density of 1.20-1.25 (30-70°C, measured by a Pomeranian specific gravity meter), and flow it into the belt dryer at a speed of 200kg / h. The heating temperature of the first section of the belt dryer is set at 90-100°C; the heating temperature of the second section is set at 70-80°C; the heating temperature of the third section is set at 50-60°C, and the dry paste after drying in the third section is collected, with a dry paste rate of 24-27%.
[0068] (3) Grinding: Take the dry paste, grind it with a water-cooled grinder, grind it through an 80-100 mesh sieve for later use (preferably an 80 mesh sieve), and obtain the ointment powder.
[0069] (4) Dry granulation: The inclusion compound powder, the ointment powder, the prescribed amount of cross-linked polyvinylpyrrolidone, the prescribed amount of microcrystalline cellulose and pregelatinized starch (add appropriate amount according to the total amount) are mixed in a three-dimensional motion mixer for 10-20 minutes (preferably 15 minutes), the mixer speed is 40-60 rpm (preferably 50 rpm), and the mixed materials are added to a dry granulator for granulation. The granulator is set with conventional technical parameters: roller pressure 210-230 bar, roller gap 0.4-1.3 mm, feed speed 20-26 rpm, screw feed speed 80-100 rpm, roller speed 20-28 rpm, crushing speed 70-90 rpm, granulation speed 70-90 rpm), and granulation mesh size is 20 mesh.
[0070] (5) Total mixing: Add the granulated granules and the prescribed amount of magnesium stearate into a three-dimensional motion mixer and mix for 10-20 minutes (preferably 15 minutes). Set the mixer speed to 40-60 rpm (preferably 50 rpm) to obtain a total mixture.
[0071] (6) Tablet pressing: Add the total mixture into the hopper of the high-speed tablet press, and each tablet weighs 0.5g. Before tablet pressing, a test run should be carried out to check the tablet weight (take 20 tablets each time and accurately weigh each tablet) and appearance, and adjust the pressure to 80KN-140KN (subsequent experimental studies use a pressure of about 140KN). After meeting the requirements, tablet pressing is carried out according to the tablet pressing process parameters. The pressed tablets are sieved with a tablet sifter to remove powder and particles. The qualified tablets are placed in a clean container, sealed, weighed, and labeled with the product name, specification, quantity, production time, etc., and then handed over to the coating process.
[0072] (7) Film coating: operate according to the "BGB-350C High-efficiency Coating Machine Standard Operating Procedure / SOP-SB074". Take the plain tablets and pour them into the coating machine, set the technical parameters such as the air inlet temperature and the coating drum speed, set the air inlet temperature to 40-50°C, turn on the heating, rotate the coating machine at a low speed, adjust the peristaltic pump speed to spray the coating slurry evenly on the plain tablets until the coating slurry is used up, turn off the heating, continue to cool the air inlet to below 35°C, stop the coating operation, check the tablet weight difference and disintegration time, put the film-coated tablets into a clean container, seal, weigh, and affix material labels as required to obtain Shugan Shunqi Tablets.
[0073] Example 3
[0074] This embodiment provides a preparation method for a capsule of a soothing liver and relieving qi composition:
[0075] The distilled oil phase and the extract obtained in Example 1 (obtained using the optimal process parameters) were used to prepare liver-soothing and qi-soothing composition capsules.
[0076] The auxiliary materials and dosage ranges used in preparing capsules are: 20-30 parts of pregelatinized starch (30 parts in the specific experiment). When preparing the total mixture, micro-powder silica gel is added, and its dosage is 3-4% of the total mixture (3% in this embodiment), and the capsule shell uses the conventional gastric soluble capsule shell in the prior art.
[0077] The preparation method is as follows:
[0078] The preparation of the distilled oil phase inclusion compound, the concentration and drying of the ointment, and the pulverization are the same as in Example 2, and the remaining steps are carried out as follows:
[0079] Dry granulation: Take the inclusion powder, ointment powder and the prescribed amount of pregelatinized starch in a three-dimensional motion mixer and mix them for 10-20 minutes (preferably 15 minutes), the mixer speed is 40-60 rpm (preferably 50 rpm), and the mixed materials are added to the dry granulator for granulation. The technical parameters of the granulator are set as follows: pressure of the pressing wheel 210-230 bar, the gap of the pressing wheel 0.4-1.3 mm, the feeding speed 20-26 rpm, the screw feeding speed 80-100 rpm, the pressing roller speed 20-28 rpm, the crushing speed 70-90 rpm, the granulation speed 70-90 rpm, and the granulation is passed through a 40-mesh sieve.
[0080] Total mixing: Add the dry granulated granules and micro-powdered silica gel into a three-dimensional motion mixer and mix for 10-20 minutes (preferably 15 minutes). Set the mixer speed to 40-60 rpm (preferably 50 rpm) to obtain the total mixture after mixing.
[0081] Filling: Fill the total mixture into No. 0 capsules (0.5 g / capsule) to prepare liver-soothing and qi-soothing composition capsules.
[0082] Example 4
[0083] This embodiment provides a preparation method for a soothing liver and relieving qi oral liquid composition:
[0084] The distilled oil phase and the extract obtained in Example 1 (obtained using the optimal process parameters) were used to prepare a liver-soothing and qi-soothing composition oral liquid.
[0085] The auxiliary materials and dosage ranges used in preparing the oral liquid are: sweetener 0.8-1.0% (sucralose / stevioside / saccharin sodium / sodium cyclamate and other single sweeteners can be selected, and composite sweeteners formed by any two or more of the above can also be selected. Different types can be added in different amounts, see Experimental Example 3 for details), sodium benzoate 0.6-1.0‰ (0.8‰ is used in the specific experiment), flavor 0.3-0.6% (0.5%, strawberry flavor is used in the specific experiment). The aforementioned "%" represents the mass percentage of the auxiliary material in the oral liquid.
[0086] The specific preparation process is as follows:
[0087] (1) Preparation of distilled oil phase inclusion compound: Take 3-5 times (preferably 4 times) the mass of distilled oil phase hydroxypropyl-β-cyclodextrin, dissolve it in 1.5-2.5 times the mass of water (preferably 2 times the mass), slowly add the distilled oil phase dropwise (0.5-3 ml / min, preferably controlling the speed within the range of 1-2 ml / min) under stirring (40-60 rpm, preferably 50 rpm), after the addition is complete, stir for 1.5-2.5 hours (preferably 2 hours) to obtain a distilled oil phase hydroxypropyl-β-cyclodextrin inclusion compound solution for use.
[0088] (2) Concentration and drying: Take the extract and start the single-effect concentrator, with the vacuum degree ≤-0.09 MPa, temperature ≤75°C, and steam pressure ≤0.30 MPa. Filter the extract through a bag filter with a mesh size of 250 and transfer it into a single-effect concentrator to concentrate it to a fluid extract with a relative density of 1.20-1.25 (30-70°C, measured by a Pomeranian pycnometer) for later use.
[0089] (3) Preparation of oral solution: Take the above fluid extract into a sugar dissolving tank, boil and sterilize for 30 minutes, cool, add the inclusion compound solution prepared by distilling the oil phase, add sweetener, preservative and pH adjuster (adjust the pH value to 4-5), make up to the mark, stir evenly, filter three times with a tubular centrifuge, then fill and sterilize, and package after passing the light inspection.
[0090] Example 5
[0091] This embodiment provides a preparation method for a liver-soothing and qi-regulating composition granule:
[0092] The distilled oil phase and the extract obtained in Example 1 (obtained using the optimal process parameters) were used to prepare the liver-soothing and qi-soothing composition granules.
[0093] The auxiliary materials and dosage ranges used in preparing the granules are: sweetener 0.04-0.06% (sucralose / stevioside / sodium cyclamate and other single sweeteners can be selected, or a composite sweetener formed by a combination of any two or more of the above can be selected, and different types can be added in different amounts, see Experimental Example 3 for details), flavor 0.3-0.6% (0.5% is used in the specific experiment), dextrin 73%-78% (76% is added in subsequent experiments, strawberry flavor). The aforementioned "%" represents the mass percentage of the auxiliary material in the granules.
[0094] The specific preparation process is as follows:
[0095] When preparing granules, the method for obtaining inclusion compound powder and ointment powder (concentration, drying and pulverization) is the same as that in Example 2, and then wet granulation is performed:
[0096] Wet granulation: put the sweetener, flavor, dextrin and ointment powder into a high-efficiency wet granulator, stir and mix at low speed (800 rpm) for 3-5 minutes, add appropriate amount of purified water, stir at high speed for 1-2 minutes (1600 rpm), and use high-speed cutter (3000 rpm) to shear evenly, discharge the material, and pass it through a 16-mesh swing granulator.
[0097] Drying: Set the air inlet temperature of the boiling dryer to 100±10℃; keep the particles in a boiling state, inhale the wet particles, and then maintain the material temperature at 60℃-80℃ until the moisture content is within 5.0%; cool the material and discharge it to obtain mixed particles.
[0098] Granulation and total mixing: The dried granules are sieved with a 16-mesh sieve, and the granules and the distilled oil phase inclusion compound powder are added to a three-dimensional motion mixer, and mixed for 10-20 minutes (preferably 15 minutes), and the mixer speed is set to 40-60 rpm (preferably 50 rpm), and the total mixture is obtained after mixing.
[0099] Packaging: Pack the granules into aluminum-plastic composite bags (3g / bag).
[0100] Experimental Example 1
[0101] Study on the extraction process of distilled oil phase (preparation of distilled oil phase by intermittent distillation extraction):
[0102] The distilled oil phase extraction method of this experimental example was carried out in the same manner as in Example 1 (using preferred parameters), except that the intermittent distillation extraction process was slightly changed, and 20 kg of medicinal materials were extracted (each medicinal material was prepared according to the formula ratio), see Table 2 for details.
[0103] Table 2: Experimental results of distillation oil phase extraction process research
[0104]
[0105]
[0106] The above experimental results show that:
[0107] In terms of distillation firepower, the inventors found that: in the process of distillation and extraction of medicinal materials, if fierce fire distillation extraction is used throughout the process, the efficiency of obtaining the distilled oil phase is not ideal, and the properties of the obtained distilled oil phase are turbid and of poor quality (see number 1). If the method of micro-boiling distillation extraction is used throughout the process, although the obtained distilled oil phase is clear, the amount of distilled oil phase obtained is too small (see number 3). It can be seen that whether it is a more intense extraction condition or a milder extraction condition for continuous distillation and extraction of medicinal materials, the amount of distilled oil phase obtained is not ideal (no more than 20mL). In the attempt of number 2, fierce fire distillation extraction and micro-boiling distillation extraction are carried out alternately, and it is found that this method can effectively increase the extraction amount of the distilled oil phase to 21mL. This is something that the inventors did not expect in advance. Generally speaking, strengthening the intensity of distillation extraction can effectively increase the distillate amount of volatile oil. Therefore, according to conventional thinking, the expected yield of distilled oil phase obtained by intermittent distillation extraction of number 2 will be between the results of number 1 and number 3, but in fact the effect of number 2 exceeds number 1 and number 3, and the unpredictable technical effect of increasing the extraction amount of distilled oil phase is obtained.
[0108] In view of the intermittent distillation extraction method, the inventors further tested the interval time of intermittent distillation. Specifically, it is more appropriate to select a distillation fire interval of 10-20 minutes and a distillation of 3-6 hours (see No. 2, No. 5-7). If the frequency of alternating between fierce fire distillation extraction and slightly boiling distillation extraction is too low (see No. 8, the interval time is 30 minutes), the extraction amount of the distilled oil phase will also be unsatisfactory, and even less than the amount of distilled oil phase obtained by the full fierce fire distillation extraction of No. 1.
[0109] In addition, the inventors have also tried to extract the raw materials of medicinal materials containing more volatile oil in the formula separately (see No. 9), and the amount of distilled oil phase obtained is slightly higher than No. 4. The inventors analyzed that the reason may be that if all the medicinal materials are distilled and extracted together, there may be certain compatibility reactions between the medicinal materials, resulting in a certain decrease in the yield of the total distilled oil phase. However, batch extraction increases the complexity of the process for large-scale production, so this method was not finally adopted. The effect of extracting medicinal materials containing distilled oil phase components separately is similar to that of combined extraction, so considering combined extraction can reduce the process and save production costs.
[0110] Finally, the inventors also tried to extract all the medicinal materials by distillation with fierce fire in the first half and by distillation with slight boiling in the second half (see No. 10), but the extraction effect of the distilled oil phase was not satisfactory. Therefore, it is not possible to increase the yield of the distilled oil phase (and ensure the quality of the distilled oil phase) by alternating the distillation with fierce fire and by slight boiling at will.
[0111] Therefore, when preparing the liver-soothing and gas-soothing preparation, the preferred method of extracting the distilled oil phase is: using a distillation fire that is intermittently circulated for 10-20 minutes and a total distillation time of 3-6 hours. The inventors have also preliminarily analyzed the reasons why the above method can increase the amount of distilled oil phase obtained, which may be as follows: the volatile oil in the medicinal material is boiled out by a slow fire, which will float or dissolve in hot water in small amounts. After a certain amount is accumulated, a fierce fire is used for boiling, and the accumulated volatile oil is concentrated and distilled back into the collector for cooling and collection. If a fierce fire is used for boiling all the time, due to the large extractor, the amount of volatile oil is very small, and some volatile oil may stay on the wall of the extractor and is not easy to return to the collector, so the amount is relatively small. For a long time, the substances may react with each other to cause the volatile oil to become turbid. If the distillation is always slow, the distillation strength is not enough, and it is not easy to distill and collect a large amount of volatile oil.
[0112] Experimental Example 2
[0113] The preparation process of the extract (adjustment of pH value during the second decoction extraction) was studied in the following manner:
[0114] (1) The extract was prepared according to the optimal process of Example 1 of the present invention, wherein, during the second water decoction extraction, the pH value of the mixture of the residue and water was adjusted to 7.2. After the final extract was obtained, the extract was concentrated into an extract (60° C., density 1.30).
[0115] The content of the main drug Magnolia officinalis (calculated as magnolol) in the extract, as well as the identification spots of costusroot, citron, Corydalis yanhusuo, peony root and liquorice were determined.
[0116] The determination method refers to the quality standard of Shugan Shunqi Pills (WS-11169 (ZD-1169)-2002-2011Z) to detect the thin layer identification of costusroot, citron, corydalis, peony, liquorice, and magnolol content. The specific experimental results are shown in Table 3.
[0117] (2) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the second water decoction extraction, the pH value of the mixture of the residue and water was not adjusted, and decoction extraction was performed directly.
[0118] (3) The extract was prepared according to the optimal process of Example 1 of the present invention, except that the pH value of the mixture of the residue and water was adjusted to 7.2 during the first and second water decoction extractions, and the pH value of the extraction system was also adjusted to 7.2 during the intermittent distillation extraction process.
[0119] (4) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the second water decoction extraction, the pH value of the mixture of the medicinal residue and water was adjusted to 6.5.
[0120] (5) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the second water decoction extraction, the pH value of the mixture of the medicinal residue and water was adjusted to 8.0.
[0121] (6) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the second water decoction extraction, the pH value of the mixture of the medicinal residue and water was adjusted to 7.0.
[0122] (7) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the second water decoction extraction, the pH value of the mixture of the residue and water was adjusted to 7.5.
[0123] (8) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the intermittent distillation extraction, the pH value of the mixture of the medicinal material and water was adjusted to 7.5, and the pH value was not adjusted in the remaining extraction steps.
[0124] (9) The extract was prepared according to the optimal process of Example 1 of the present invention, except that during the first water decoction extraction, the pH value of the mixture of the residue and water was adjusted to 7.5, and the pH value was not adjusted in the remaining extraction steps.
[0125] (10) The extract was prepared according to the optimal process of Example 1 of the present invention, except that: during the intermittent distillation extraction, the pH value of the mixture of the medicinal material and water was adjusted to 7.5; during the first water decoction extraction, the pH value of the mixture of the medicinal residue and water was adjusted to 7.5; and the pH value was not adjusted in the remaining extraction steps.
[0126] Table 3: Quality test results of Shugan Shunqi ointment
[0127]
[0128]
[0129] In the above experimental attempts, experiments (1), (6) and (7) were all carried out according to the operation method of this scheme. During the second decoction and extraction process, the pH value of the system consisting of the residue and water was adjusted to 7.0-7.5. This operation method is very effective in ensuring the transfer rate of costus root, citron, yanhusuo, peony root, liquorice and magnolia bark, and increasing the content of the effective ingredients of magnolia bark in the extract (i.e., the extract).
[0130] In experiment (2), the pH value of the system composed of the residue and water of the second decoction extraction was not adjusted, which would result in a decrease in the content of Magnolia officinalis, and the identification spots of costus root and Corydalis yanhusuo were relatively weak, indicating that the extraction method would affect the transfer rate of Magnolia officinalis, costus root and Corydalis yanhusuo. In experiment (8), only the pH value of the extraction system of distillation extraction was adjusted to 7.5. In experiment (9), only the pH value of the first decoction extraction was adjusted to 7.5. In experiment (10), only the pH value of the first decoction extraction and the pH value of the extraction system of distillation extraction were adjusted to 7.5. None of the above experimental attempts adjusted the pH value of the system composed of the residue and water of the second decoction extraction to the specified range, which would result in a significant decrease in the content of the effective components of Magnolia officinalis in the extract (i.e., the extract). On this basis, adjusting the pH value of other extraction process steps will not alleviate the phenomenon of a significant decrease in the content of the effective components of Magnolia officinalis, and may even affect the transfer effect of costus root and Corydalis yanhusuo to varying degrees.
[0131] In experiment (4), the pH value of the system composed of the residue extracted from the second decoction and water was adjusted to a lower level (6.5), and in experiment (5), the pH value of the system composed of the residue extracted from the second decoction and water was adjusted to a higher level (8.0). The above experimental results show that: adjusting the pH value too high or too low will have a negative impact on the content of Magnolia bark in the ointment, but has no effect on the transfer of the identification components.
[0132] In experiment (3), the pH value of the extraction system for both the double decoction extraction and the distillation extraction was adjusted to 7.2. The above experimental results show that if the pH value of the three extraction systems is adjusted, the spots for identification of costusroot and yanhusuo will be relatively weak, but the content of magnolia bark is not significantly affected.
[0133] The above experimental results indicate that, during the extract preparation stage, the pH value of the extraction system for the second decoction extraction needs to be adjusted to ensure the extraction rate of the active ingredients.
[0134] Experimental Example 3
[0135] Formulation research
[0136] (1) Preparation of inclusion complexes
[0137] The preparation process of the inclusion compound powder refers to the best implementation method of Example 2. The types of inclusion agents were studied, and the effects of hydroxypropyl-β-cyclodextrin and β-cyclodextrin in preparing inclusion compounds were studied respectively. The selection of specific parameters and experimental results are shown in Table 4.
[0138] Table 4: Selection of inclusion compound prescriptions
[0139]
[0140] The research results show that the encapsulation / solubilization effect of hydroxypropyl-β-cyclodextrin on the distilled oil phase of this product is better than that of β-cyclodextrin, so hydroxypropyl-β-cyclodextrin was selected to prepare the inclusion complex.
[0141] (2) Tablet prescription study
[0142] The disintegrant used in preparing the tablets was screened, and the formula composition is shown in Table 5. In Table 5, the "extracted ointment" is the ointment powder prepared in the optimal way in Example 2.
[0143] Table 5: Disintegrant Screening Formulation
[0144]
[0145] The preparation process is shown in Example 2. During the test, the particle formability of the dry granulation, the disintegration performance of the plain tablet, the tableting phenomenon, the friability, etc. are tested. The test results are shown in Table 6.
[0146] Table 6: Disintegrant screening test results
[0147]
[0148] The research results show that among the same amount of cross-linked polyvinylpyrrolidone, cross-linked sodium carboxymethyl cellulose, low-substituted hydroxypropyl cellulose and sodium carboxymethyl starch, cross-linked polyvinylpyrrolidone has the strongest disintegration ability in this product. Therefore, cross-linked polyvinylpyrrolidone was selected for further research, and the disintegration conditions of different amounts were considered respectively.
[0149] Take 25 parts of the extracted ointment powder, a certain amount of cross-linked polyvinylpyrrolidone (see Table 7), 15 parts of microcrystalline cellulose, a certain amount of pregelatinized starch (see Table 7), about 0.4 parts of the inclusion compound powder prepared in Scheme 1, and 1.35 parts of magnesium stearate, and conduct research according to Table 7.
[0150] Table 7: Drug prescriptions containing different amounts of cross-linked polyvinylpyrrolidone
[0151]
[0152] The preparation process refers to the optimal process scheme of Example 2. During the test, the particle formability of dry granulation, the disintegration performance of plain tablets, tablet compression phenomenon, friability, etc. were tested. The test results are shown in Table 8.
[0153] Table 8: Drug performance test results containing different amounts of cross-linked polyvinylpyrrolidone
[0154]
[0155] The research results show that the disintegration performance of 4-8 parts of cross-linked polyvinylpyrrolidone is relatively stable.
[0156] (3) Capsule prescription research
[0157] The fillers used to prepare the capsules were screened, and the formula composition is shown in Table 9.
[0158] Table 9: Filler Screening Formula
[0159]
[0160] The preparation process refers to the optimal process scheme of Example 3. During the test, the particle formability of dry granulation, the disintegration performance of the capsule, the filling condition, the disintegration, etc. are tested. The test results are shown in Table 10.
[0161] Table 10: Filler screening test results
[0162]
[0163] The results show that, for the same amount of pregelatinized starch, corn starch, dextrin, microcrystalline cellulose and lactose, pregelatinized starch and lactose as fillers have better disintegration and are evenly dispersed after disintegration. When corn starch and dextrin are used as fillers, the capsules stick to the bottom of the disintegration basket, and the capsules prepared by microcrystalline cellulose float on the top of the disintegration basket, resulting in slower disintegration. Therefore, the commonly used pregelatinized starch was selected as the filler of this product.
[0164] (4) Granule prescription research
[0165] Take 25 parts of the extracted ointment powder, 74.05 parts of the filler, 0.05 parts of the sweetener, 0.5 parts of the strawberry flavor, and about 0.4 parts of the inclusion compound powder prepared in Scheme 1 (Table 4). The experimental prescription is shown in Table 11.
[0166] Table 11: Sweetener screening formula
[0167]
[0168]
[0169] The preparation process is shown in Example 2. The granulation property, solubility and mouthfeel of the particles are tested during the test. The test results are shown in Table 12.
[0170] Table 12: Granular sweetener screening test results
[0171]
[0172] The results of the study indicate that the use of dextrin as a filler, sucralose, stevioside and sodium cyclamate alone or in combination with strawberry flavor can produce granules with good particle forming properties, acceptable solubility and good taste, which are acceptable to humans.
[0173] (5) Study on the prescription of oral solution
[0174] Take 25 parts of the extracted ointment powder, 0.05 parts of the sweetener, 0.5 parts of the strawberry flavor, and about 0.4 parts of the inclusion compound powder prepared in Scheme 1 (Table 4). See Table 13 for the experimental prescription.
[0175] Table 13: Screening formula for oral liquid sweeteners
[0176]
[0177]
[0178] The preparation process is shown in Example 5. During the test, properties, low-temperature freeze-thaw cycle tests, and long-term storage stability at room temperature are carried out. The test results are shown in Table 14.
[0179] Table 14: Oral liquid sweetener screening test results
[0180]
[0181] The research results show that oral liquids with stable properties, good taste and good quality stability can be prepared by using sucralose, stevioside and sodium cyclamate alone or in combination of two, sodium benzoate and strawberry flavor.
[0182] Experimental Example 4
[0183] Shugan Shunqi Pills are pure Chinese medicine preparations (approval number: National Medicine Standard Z20026802) produced and marketed by Chongqing Xieran Pharmaceutical Co., Ltd. It is an over-the-counter Class A drug. The approved [Functions and Indications] in its instructions are to soothe the liver, regulate qi, and relieve pain. It is used for fullness in the ribs, stomach pain, vomiting, and warming heartburn caused by liver depression and qi stagnation. Clinical medication has found that it can be used to treat functional dyspepsia. Therefore, this example conducts a character pharmacodynamic study by establishing an animal model of functional dyspepsia, as follows:
[0184] 4.1 Experimental animals and groups
[0185] Experimental animals: 80 SPF SD rats (weight 200±20g), male, were randomly divided into a blank control group (n=20) and a modeling group (n=60) after adaptive feeding for one week. The rats in the modeling group were stimulated by the following method: the distal 1 / 3 of the tail of the modeling rats was clamped with a butterfly clamp, so that the rats became furious and fought with each other, and the degree of clamping the tail without breaking the skin was considered as the limit. Each stimulation lasted for half an hour, 4 times a day, for 14 consecutive days, and the rats' status was observed and recorded regularly.
[0186] Modeling method: The rat functional dyspepsia (liver depression and qi stagnation) model was replicated by referring to the mouse tail clamping method in the prior art literature (Liu Jing, Li Feng, Tang Xudong, et al. Overview of animal models of functional dyspepsia and their application in traditional Chinese medicine research [J]. Global Chinese Medicine, 2013, 6(12): 955-958.).
[0187] Grouping and administration: After the modeling was completed, the modeling group rats were randomly divided into a model control group, a Shugan Shunqi pill group (commercially available product), and a Shugan Shunqi tablet group (tablets prepared in Example 2), with 20 rats in each group. Administration began on the day the modeling was completed. The blank control group and the model control group were given corresponding volumes of purified water, and the other drug administration groups were all given a dose of 1.33 g crude drug / kg (calculated in crude drug amount), and the drug was administered once a day by gavage for 14 consecutive days. During the administration process, rats in each group were free to drink water and eat.
[0188] 4.2 Experimental results and observations
[0189] 4.2.1 Observation of the effects of each group of drugs on the weight gain of functional dyspepsia rat model
[0190] During the administration period, the rats were observed daily and weighed once a week. Compared with the blank control group, the rats in the model control group showed irritability, unkempt hair, lack of appetite, loose stools, slow weight gain, etc., indicating that the functional dyspepsia (liver depression and qi stagnation type) model was successfully established. After 2 weeks of administration, the symptoms of irritability, unkempt hair, lack of appetite, loose stools, etc. in the rats in each dose group of Shugan Shunqi Pills were significantly improved, and the weight changes of the rats in each group after administration are shown in Table 15.
[0191] Table 15: Effect of the Shugan Shunqi Composition on Body Weight Changes in Functional Dyspepsia Model Rats (x-±SD)
[0192]
[0193]
[0194] Note: Compared with the model control group, * p<0.05, ** p<0.01;
[0195] According to the above experimental results, the Shugan Shunqi composition (including Shugan Shunqi large honey pills and Shugan Shunqi tablets) provided by the present invention has a good therapeutic effect on improving functional dyspepsia. At the same time, the changes in rat body weight after administration show that the improved Shugan Shunqi tablets have a better effect on improving functional dyspepsia.
[0196] 2.2.2 Observation of the effects of each group of drugs on gastric juice indexes of rats with functional dyspepsia
[0197] ①Gastric fluid volume measurement:
[0198] After the last administration, the rats were fasted but not watered for 16-18 hours, then killed by cervical dislocation, the whole stomach was cut out, the gastric juice was taken out and placed in a graduated centrifuge tube, centrifuged at 3000 rpm for 15 min, the supernatant was the total amount of gastric juice secreted by the rats in 5 hours, expressed in ml, and the amount of gastric juice was recorded.
[0199] ② Gastric juice acidity (total acidity and total acid excretion) determination:
[0200] Take 1 ml of the above centrifuged gastric juice and place it in a small triangular flask. Place the flask on white backing paper, add one drop of phenol red indicator, and titrate with 0.01 mol / L NaOH until the gastric juice changes from reddish to orange-yellow, and then from yellow to reddish within 2 seconds without fading (the end point of total acidity in gastric juice). Record the amount of sodium hydroxide consumed, and calculate the total acidity and total acidity discharge.
[0201] Total acidity (moL / L) = sodium hydroxide consumption
[0202] Total acid excretion in 1 hour (moL / L / h) = total acidity x gastric juice volume / 5
[0203] ③ Pepsin activity (PP) determination:
[0204] The gastric juice was collected after centrifugation, and the pepsin activity of rats in each group was determined using a commercially available pepsin kit.
[0205] The experimental results are shown in Table 16:
[0206] Table 16: Effects of each group of drugs on gastric juice indexes in functional dyspepsia rat model (x-±SD)
[0207]
[0208]
[0209] Note: Compared with the model control group, * p<0.05, ** p<0.01;
[0210] From the above experimental results, it can be seen that compared with the model control group, there is no significant difference in the secretion of gastric juice in each group of rats. At the same time, the model control group has a significant decrease in gastric acidity and pepsin activity compared with the blank control group, while the total acid excretion in 1h has a significant increase. The Shugan Shunqi large honey pill dosage form and tablet dosage form provided by the present invention can effectively increase gastric acidity and pepsin activity, and can effectively reduce the total acid excretion in 1h of rats, and the Shugan Shunqi tablets are better than the Shugan Shunqi large honey pill dosage form.
[0211] 2.2.3 Observation of the effects of each group of drugs on gastrointestinal motility in rats with functional dyspepsia
[0212] 20 minutes after the last administration, 5 mL / rat of black semisolid paste (containing black activated carbon powder) was gavaged. 20 minutes later, rats were killed by dislocation of the neck, the abdomen was opened, and the gastric cardia and pylorus were ligated. The stomach was taken out, and the total weight of the stomach was weighed after drying with filter paper. Then the stomach body was cut open along the greater curvature of the stomach, the stomach contents were washed out and wiped dry, and the net weight of the stomach was weighed. The difference between the total weight of the stomach and the net weight of the stomach was the weight of the residual content in the stomach, and the residual rate in the stomach was calculated based on this. At the same time, the small intestine was quickly taken out, and the total length from the pylorus to the ileocecal part and the distance from the pylorus to the front of the black semisolid paste were measured. The small intestinal propulsion rate was calculated as the percentage of the distance from the pylorus to the front of the black semisolid paste to the total length from the pylorus to the ileocecal part.
[0213] Table 17: Effects of each group of drugs on gastrointestinal motility in rats with functional dyspepsia (x-±SD)
[0214]
[0215] Note: Compared with the model control group, * p<0.05, ** p<0.01;
[0216] From the above experiments, it can be seen that compared with the model control group, the gastric residual rate of the blank control group was significantly lower than that of the model control group, and the small intestinal propulsion rate was also significantly higher than that of the model control group. After administration of the Shugan Shunqi composition, compared with the model control group, the Shugan Shunqi large honey pill group and the Shugan Shunqi tablet group can effectively improve the small intestinal propulsion rate and significantly reduce the gastric residual rate, indicating that the Shugan Shunqi composition can enhance the gastrointestinal motility of experimental animals and significantly improve the pharmacological effect of functional dyspepsia.
[0217] Based on the above results, it is speculated that in improving the gastric juice secretion index and gastrointestinal motility index of rats, Shugan Shunqi tablets show better technical effects than Shugan Shunqi large honey pills in terms of the degree of improvement of indicators. It is considered that the reason may be that the tablet dosage form provided by the present invention effectively retains various volatile oil components in the original medicinal raw materials through distillation extraction. At the same time, in the preparation process of the tablets, by controlling the pH during the decocting process of the medicinal residue, the efficient transfer and retention of components such as magnolia bark phenol is achieved, thereby achieving a further improvement in the efficacy of the Shugan Shunqi preparation, which has great positive significance for the clinical application of the Shugan Shunqi composition.
[0218] The above is only an embodiment of the present invention, and the common knowledge such as the known specific technical solutions and / or characteristics in the solution is not described in detail here. It should be pointed out that for those skilled in the art, several modifications and improvements can be made without departing from the technical solution of the present invention, which should also be regarded as the protection scope of the present invention, and these will not affect the effect of the implementation of the present invention and the practicality of the patent. The scope of protection required by this application shall be based on the content of its claims, and the specific implementation methods and other records in the specification can be used to interpret the content of the claims.
Claims
1. A method for preparing a liver-soothing and qi-regulating preparation, characterized in that: The method includes the following steps in sequence: S1: extracting the medicinal material by distillation to obtain a distilled water phase, a distilled oil phase and medicinal residues; extracting the medicinal residues by decocting in water to obtain a decoction, and combining the decoction and the distilled water phase to obtain an extract; S2: using an inclusion agent to carry out inclusion treatment on the distilled oil phase to obtain an inclusion compound solution or inclusion compound powder; After the extract is concentrated, it is prepared into an oral preparation together with an inclusion compound solution or inclusion compound powder and auxiliary materials.
2. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In S1, the medicinal raw materials include, by weight: 25-35 parts of Magnolia officinalis, 25-35 parts of Chuanxiong, 25-35 parts of Cyperus rotundus, 25-35 parts of White Peony Root, 25-35 parts of Bupleurum Root, 25-35 parts of Citrus aurantium, 25-35 parts of Curcuma Radix, 25-35 parts of Citrus Hand, 25-35 parts of Aucklandia Root, 25-35 parts of Tangerine Peel, 20-30 parts of Licorice, 25-35 parts of Corydalis and 55-65 parts of Amaranthus; Preferably, the medicinal raw materials include: 31.4 parts of Magnolia officinalis, 31.4 parts of Chuanxiong, 31.4 parts of Cyperus rotundus, 31.4 parts of White Peony Root, 31.4 parts of Bupleurum Root, 31.4 parts of Citrus aurantium, 31.4 parts of Curcuma Radix, 31.4 parts of Citrus Hand, 31.4 parts of Aucklandia Root, 31.4 parts of Tangerine Peel, 23.55 parts of Licorice, 31.4 parts of Corydalis yanhusuo and 58.85 parts of Amaranthus orchioides.
3. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In S1, the distillation extraction adopts an intermittent distillation extraction method, and the intermittent distillation extraction is performed alternately by fierce fire distillation and slight boiling distillation; Preferably, the intermittent distillation extraction uses water or an alcohol solution as the extraction solvent; Preferably, the total extraction time is 1-8 hours; Preferably, the intermittent distillation extraction process is carried out in a cycle of first 10-20 minutes of high-fire distillation extraction and then 10-20 minutes of micro-boiling distillation extraction.
4. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In step S1, the method for extracting the medicinal residue by decoction in water is specifically as follows: adding water 6-8 times the mass of the medicinal raw material to perform a first decoction extraction for 2-3 hours; adding water 6-8 times the mass of the medicinal raw material and adjusting the pH value to 7.0-7.5, performing a second decoction extraction for 2-3 hours, and mixing the extracts obtained by the first decoction extraction and the second decoction extraction to obtain a decoction.
5. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In S2, the oral preparation is a liver-soothing and gas-soothing composition tablet, which is prepared by the following steps: S2-1-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution or concentrate and dry the inclusion compound solution to obtain an inclusion compound powder; The extract is concentrated and then dried to obtain a dry paste, and the dry paste is crushed and sieved to obtain ointment powder; S2-1-2: taking the inclusion compound solution or inclusion compound powder, the ointment powder and the granulation excipients and mixing them evenly, and then granulating them to obtain drug granules; Preferably, the granulation excipients include cross-linked polyvinylpyrrolidone and microcrystalline cellulose; S2-1-3: mixing the drug particles and tableting excipients at 15-20 rpm for 10-20 minutes to obtain a total mixture; Preferably, the tableting auxiliary material is magnesium stearate; S2-1-4: The total mixture is subjected to tableting and coating treatment to obtain liver-soothing and qi-regulating composition tablets.
6. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In S2, the oral preparation is a capsule of the soothing liver and shunning qi composition, which is prepared by the following steps: S2-2-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution or concentrate and dry the inclusion compound solution to obtain an inclusion compound powder; The extract is concentrated and then dried to obtain a dry paste, and the dry paste is crushed and sieved to obtain ointment powder; S2-2-2: taking the inclusion compound solution or inclusion compound powder, the ointment powder and the pregelatinized starch, mixing them evenly and granulating them to obtain drug granules; S2-2-3: mixing the drug particles and the micro-powdered silica gel to obtain a total mixture; S2-2-4: Fill the total mixture into empty capsules to obtain liver-soothing and qi-regulating composition capsules.
7. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In S2, the oral preparation is a soothing liver and shunning qi composition oral liquid, which is prepared by the following steps: S2-3-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution or concentrate and dry the inclusion compound solution to obtain an inclusion compound powder; Concentrating the extract into an extract or a fluid extract; S2-3-2: Take the extract or fluid extract, inclusion compound solution or inclusion compound powder, sweetener, and preservative, mix them, and adjust the pH value to 4-5. After fixing the volume, filter and sterilize to obtain the oral liquid of soothing liver and relieving qi composition.
8. The method for preparing a liver-soothing and qi-regulating preparation according to claim 1, characterized in that: In S2, the liver-soothing and qi-soothing composition granules are prepared by the following steps: S2-4-1: Take 3-5 times the mass of the distilled oil phase of hydroxypropyl-β-cyclodextrin, and dissolve it in 3-5 times the mass of water of the hydroxypropyl-β-cyclodextrin; add the distilled oil phase dropwise under stirring, and stir for 1-3 hours after the addition is complete to obtain an inclusion compound solution, and then concentrate and dry the inclusion compound solution to obtain an inclusion compound powder; The extract is concentrated and then dried to obtain a dry paste, and the dry paste is crushed and sieved to obtain ointment powder; S2-4-2: taking the sweetener, flavor, filler, inclusion compound powder and ointment powder, and wet granulating and drying them to obtain mixed granules; preferably, the filler is any one of dextrin or soluble starch; S2-4-3: Mix the mixed granules and the inclusion compound powder to obtain a total mixture, and prepare the liver-soothing and qi-regulating composition granules.
9. The Shugan Shunqi preparation prepared by the method for preparing the Shugan Shunqi preparation according to any one of claims 1 to 8.
10. Use of the Shugan Shunqi preparation according to claim 9 in the preparation of a medicament for treating functional dyspepsia, or in the preparation of a medicament for treating fullness in the flanks, epigastric pain, vomiting, noisy stomach, belching and acid reflux caused by liver depression and qi stagnation.
Citation Information
Patent Citations
Medicament composition for treating hepatopathy and preparation method thereof
CN101461925A
Method for enriching and purifying rhizoma atractylodis volatile oil in rhizoma atractylodis
CN101757072A
Costus qi-regulating quick-release preparation and preparation method thereof
CN102058867A
Traditional Chinese medicine composition for treating spleen deficiency and phlegm-dampness type polycystic ovarian syndrome and preparation method thereof
CN116036152A
Powder injection contg. radix bupleuri and its prepn. method
CN1785221A
Cited By
Segmented extraction and alcohol precipitation combined preparation process of compound honeysuckle granules
CN121818548A
